Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (3): 521-529. doi: 10.19723/j.issn.1671-167X.2023.03.019

Previous Articles     Next Articles

Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma

Yun-fei SHI1,Hao-jie WANG2,Wei-ping LIU3,Lan MI3,Meng-ping LONG1,Yan-fei LIU3,Yu-mei LAI1,Li-xin ZHOU1,Xin-ting DIAO1,Xiang-hong LI1,*()   

  1. 1. Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China
    2. Central Laboratory, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China
    3. Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China
  • Received:2022-09-22 Online:2023-06-18 Published:2023-06-12
  • Contact: Xiang-hong LI E-mail:kxhli72@163.com

RICH HTML

   

PDF (PC)

Abstract:

Objective: To analyze the clinicopathological features, molecular changes and prognostic factors in angioimmunoblastic T-cell lymphoma (AITL). Methods: Sixty-one cases AITL diagnosed by Department of Pathology of Peking University Cancer Hospital were collected with their clinical data. Morphologically, they were classified as typeⅠ[lymphoid tissue reactive hyperplasia (LRH) like]; typeⅡ[marginal zone lymphoma(MZL)like] and type Ⅲ [peripheral T-cell lymphoma, not specified (PTCL-NOS) like]. Immunohistochemical staining was used to evaluate the presence of follicular helper T-cell (TFH) phenotype, proliferation of extra germinal center (GC) follicular dendritic cells (FDCs), presence of Hodgkin and Reed-Sternberg (HRS)-like cells and large B transformation. The density of Epstein-Barr virus (EBV) + cells was counted with slides stained by Epstein-Barr virus encoded RNA (EBER) in situ hybridization on high power field (HPF). T-cell receptor / immunoglobulin gene (TCR/IG) clonality and targeted exome sequencing (TES) test were performed when necessary. SPSS 22.0 software was used for statistical analysis. Results: Morphological subtype (%): 11.4% (7/61) cases were classified as type Ⅰ; 50.8% (31/61) as type Ⅱ; 37.8% (23/61) as type Ⅲ. 83.6% (51/61) cases showed classical TFH immunophenotype. With variable extra-GC FDC meshwork proliferation (median 20.0%); 23.0% (14/61) had HRS-like cells; 11.5% (7/61) with large B transformation. 42.6% (26/61) of cases with high counts of EBV. 57.9% (11/19) TCR+/IG-, 26.3% (5/19) TCR+/IG+, 10.5% (2/19) were TCR－/IG－, and 5.3% (1/19) TCR－/IG+. Mutation frequencies by TES were 66.7% (20/30) for RHOA, 23.3% (7/30) for IDH2 mutation, 80.0% (24/30) for TET2 mutation, and 33.3% (10/30) DNMT3A mutation. Integrated analysis divided into four groups: (1) IDH2 and RHOA co-mutation group (7 cases): 6 cases were type Ⅱ, 1 case was type Ⅲ; all with typical TFH phenotype; HRS-like cells and large B transformation were not found; (2) RHOA single mutation group (13 cases): 1 case was type Ⅰ, 6 cases were type Ⅱ, 6 cases were type Ⅲ; 5 cases without typical TFH phenotype; 6 cases had HRS-like cells, and 2 cases with large B transformation. Atypically, 1 case showed TCR－/IG－, 1 case with TCR－/IG+, and 1 case with TCR+/IG+; (3) TET2 and/or DNMT3A mutation alone group (7 cases): 3 cases were type Ⅱ, 4 cases were type Ⅲ, all cases were found with typical TFH phenotype; 2 cases had HRS-like cells, 2 cases with large B transformation, and atypically; (4) non-mutation group (3 cases), all were type Ⅱ, with typical TFH phenotype, with significant extra-GC FDC proliferation, without HRS-like cells and large B transformation. Atypically, 1 case was TCR－/IG－. Univariate analysis confirmed that higher density of EBV positive cell was independent adverse prognostic factors for both overall survival (OS) and progression free survival(PFS), (P=0.017 and P=0.046). Conclusion: Pathological diagnoses of ALTL cases with HRS-like cells, large B transformation or type Ⅰ are difficult. Although TCR/IG gene rearrangement test is helpful but still with limitation. TES involving RHOA, IDH2, TET2, DNMT3A can robustly assist in the differential diagnosis of those difficult cases. Higher density of EBV positive cells counts in tumor tissue might be an indicator for poor survival.

Key words: T cell, Lymphoma, Pathology, Gene mutation, Prognosis

CLC Number: 

  • R732.2

Table 1

Details in primary antibodies in immunohistochemical staining"

Primary antibody Clone Manufacturer Specified target Location Dilution
BCL6 ZR280 Beijing Xiya Golden Bridge Biotechnology TFH cell or tumor cell Cell nuclear 1:50
CD3ε A0452 Dako, Agilent Technologies, Santa Clara, USA T cell or tumor cell Cytoplasm 1:50
CD10 56C6 Dako, Agilent Technologies, Santa Clara, USA TFH cell or tumor cell Cell membrane 1:50
CD20 L26 Dako, Agilent Technologies, Santa Clara, USA B cell Cell membrane 1:50
CD21 EP64 Beijing Zhongshan Golden Bridge Biotechnology FDC cell Cell membrane 1:50
CD30 JCM182 Novocastra, Leica Biosystems, UK Immunoblastic cell Cell membrane or cytoplasm 1:50
CD4 UMAB64 Beijing Xiya Golden Bridge Biotechnology T helper cell or tumor cell Cell membrane 1:50
CXCL13 53610 R&D Systems TFH cell or tumor cell Cytoplasm 1:50
Ki67 MIB1 Dako, Agilent Technologies, Santa Clara, USA Tumor cell Cell nuclear 1:50
PD1 UMAB199 Beijing Zhongshan Golden Bridge Biotechnology TFH cell or tumor cell Cell membrane 1:50

Table 2

The clinical and pathological characteristics and outcomes of the angioimmunoblastic T-cell lymphoma (AITL) patients"

Characteristics n(%)
Age, ＞60 years 27 (44.3)
Gender, male 39 (63.9)
Ann arbor stage, Ⅲ-Ⅳ 59 (96.7)
B symptoms, yes 28 (45.9)
Skin rash, yes 19 (31.1)
IPI score, high risk (3-5) 27 (44.3)
PIT score, high risk (2-3) 32 (52.5)
ECOG score, ＞1 7 (11.5)
Nodal areas involved, ＞5 44 (72.1)
Extranodal involvement, ＞1 18 (29.5)
Bone marrow involvement, yes 13 (21.3)
LDH elevated 29 (47.5)
β2-MG elevated 40 (30.5)
Treatment
  CHOP-like 24 (39.3)
  CHOEP-like 26 (42.6)
  CHOEPG-like 10 (16.4)
  Prednisone mono-therapy 1 (1.6)
Response
  CR 27 (44.3)
  ORR 38 (62.3)
  NA 3 (4.9)
Transplant AHSCT 13 (21.3)
Histology pattern
  Pattern Ⅰ 7 (11.4)
  Pattern Ⅱ 31 (50.8)
  Pattern Ⅲ 23 (37.8)
HRS-like cell present, yes 14 (23.0)
Large B cell transformation, yes 7 (11.5)
TFH phenotype, typical 51 (83.6)
Extra FDC (CD21), ≥20% 35 (57.4)
EBV positive cell, >10/HPF 26 (42.6)
Ki67, ≥60% 24 (39.3)

Figure 1

Representative images of morphological patterns in angioimmunoblastic T-cell lymphoma (AITL) A, a case with type Ⅰ pattern: follicular hyperplasia / reactive hyperplasia, LRH-like); B, a case with type Ⅱ pattern (follicular atrophy with paracortical expansion, MZL-like); C, a case with type Ⅲ (disappearance of follicles with significant expansion of paracortical area or diffuse tumor invasion, PTCL-NOS like)."

Figure 2

Representative images of CD10, BCL6, PD1 and CXCL13 expression in the same AITL case A, strong membrane staining with CD10; B, nuclear staining with BCL6; C, bright membrane staining of PD1; D, cytoplasmic staining of CXCL13."

Figure 3

Representative images of the expanded follicular dendritic cell meshwork, HRS-like cells, large B transformation component, and EBER status in relative angioimmunoblastic T-cell lymphoma (AITL) cases A, highly expanded extra follicular FDC meshwork; B, Hodgkin and Read-Sternberg (HRS)-like cells in the canter of the picture; C, large B transformation component at low-power field(indicated by black circle); D, transformed large B cells at high-power field; E, the status of Epstein-Barr virus encoded RNA (EBER) positive cells in tumor tissue were classified as high density; F, the status of EBER positive cells in tumor tissue were classified as low density."

Figure 4

Overview of clinical, pathological and molecular genetic findings in 30 AITL cases Each column of the heat map represents one angioimmunoblastic T-cell lymphoma (AITL) case and each line the specific analysis. HRS, Hodgkin and Reed-Sternberg-like; NGS, next-generation sequencing; IHC, Immunohistochemistry; EBER, Epstein-Barr virus-encoded RNA; TFH, follicular T helper cell; EBV, Epstein-Barr virus; TCR, T cell receptor; IG, immunoglobulin; NGS, next-generration sequencing."

Figure 5

EBER status (n=61) and the mutation status of IDH2 and RHOA (n=30)in AITL tumor tissue were found associated with clinical outcomes A, patients with Epstein-Barr virus encoded RNA (EBER) positive status rated as high (>10% cell/high power field) exhibited shortened overall survival (OS); B, patients with EBER positive status rated as high (>10% cell/high power field) exhibited shortened progression free survival (PFS); C, patients with IDH2 mutation showed better prognosis in terms of OS; D, those patients with mutated RHOA related to significant prolonged PFS. Log-rank P values and number of cases analyzed were all provided. By univariate (Kaplan-Meier estimations) with the log rank test for OS in AITL patients."

Table 3

Prognostic parameters analysis for angioimmunoblastic T-cell lymphoma (AITL) (n=61)"

Characteristics OS PFS
Univariate analysis Univariate analysis
HR(95%CI) P value HR(95%CI) P value
EBV grade 2.526 (1.144-5.577) 0.022 1.873 (1.000-3.509) 0.050
Large B transformation 0.830 (0.248-2.774) 0.762 0.902 (0.351-2.317) 0.831
TFH phenotype 0.516 (0.192-1.385) 0.189 0.493 (0.205-1.186) 0.114
HRS cell 0.813 (0.324-2.036) 0.658 0.827 (0.410-1.668) 0.596
Gender 0.984 (0.426-2.272) 0.970 1.297 (0.663-2.536) 0.448
Age(>60 years) 1.664 (0.7547-3.670) 0.207 1.528 (0.817-2.855) 0.184
Skin rash 0.579 (0.232-1.446) 0.242 0.845 (0.421-1.697) 0.637
IPI (score 3-5) 2.114 (0.969-4.614) 0.060 1.365 (0.731-2.550) 0.328
PIT(score 2-3) 1.087 (0.502-2.354) 0.833 1.136 (0.607-2.126) 0.690
β2-MG elevated 2.338 (1.035-5.281) 0.041 1.948 (1.032-3.676) 0.040
Nodal areas involved >5 56.392 (2.171-1 464.673) 0.015 3.187 (1.453-6.990) 0.004
Transplant 0.191 (0.045-0.813) 0.025 0.195 (0.069-0.554) 0.002
1 Swerdlow SH , Campo E , Pileri SA , et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127 (20): 2375- 2390.
doi: 10.1182/blood-2016-01-643569
2 Laurent C , Baron M , Amara N , et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French lymphopath network[J]. J Clin Oncol, 2017, 35 (18): 2008- 2017.
doi: 10.1200/JCO.2016.71.2083
3 van Krieken JHJM , Langerak AW , Macintyre EA , et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: Report of the BIOMED-2 concerted action BHM4-CT98-3936[J]. Leukemia, 2006, 21 (2): 201- 206.
4 Langerak AW , Groenen PJTA , Brüggemann M , et al. Euro-Clonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations[J]. Leukemia, 2012, 26 (10): 2159- 2171.
doi: 10.1038/leu.2012.246
5 Cortes JR , Palomero T . The curious origins of angioimmunoblastic T-cell lymphoma[J]. Curr Opin Hematol, 2016, 23 (4): 434- 443.
doi: 10.1097/MOH.0000000000000261
6 郭艳敏, 刘雪霏, 焦莉娟, 等. 血管免疫母细胞性T细胞淋巴瘤组织学分级与预后分析[J]. 中华病理学杂志, 2019, 48 (10): 784- 790.
7 Zhang C , Mi L , Wu M , et al. Angioimmunoblastic T-cell lymphoma: Treatment strategies and prognostic factors from a retrospective multicenter study in China[J]. Leuk Lymphoma, 2022, 63 (5): 1152- 1159.
doi: 10.1080/10428194.2021.2015586
8 Hsu YT , Wang YC , Chen RY , et al. Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for RHOA G17V mutated subtype[J]. Leuk Lymphoma, 2020, 61 (5): 1108- 1118.
doi: 10.1080/10428194.2019.1702179
9 李婷婷, 罗璐婷, 陈溢, 等. 84例血管免疫母细胞性T细胞淋巴瘤的临床特征及预后: 单中心分析[J]. 中华血液学杂志, 2020, 41 (11): 915- 920.
10 Steinhilber J , Mederake M , Bonzheim I , et al. The pathological features of angioimmunoblastic T-cell lymphomas with IDH2(R172) mutations[J]. Mod Pathol, 2019, 32 (8): 1123- 1134.
doi: 10.1038/s41379-019-0254-4
11 Hsi ED , Said J , Macon WR , et al. Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project[J]. Am J Surg Pathol, 2014, 38 (6): 768- 775.
doi: 10.1097/PAS.0000000000000188
12 Heavican TB , Bouska A , Yu J , et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma[J]. Blood, 2019, 133 (15): 1664- 1676.
doi: 10.1182/blood-2018-09-872549
13 Schwartz FH , Cai Q , Fellmann E , et al. TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma[J]. J Pathol, 2017, 242 (2): 129- 133.
doi: 10.1002/path.4898
14 Palomero T , Couronne L , Khiabanian H , et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas[J]. Nature Genetics, 2014, 46 (2): 166.
doi: 10.1038/ng.2873
15 Yoo HY , Sung MK , Lee SH , et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma[J]. Nat Genet, 2014, 46 (4): 371- 375.
doi: 10.1038/ng.2916
16 Fukumoto K , Nguyen TB , Chiba S , et al. Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma[J]. Cancer Sci, 2018, 109 (3): 490- 496.
doi: 10.1111/cas.13393
17 Chiba S , Sakata-Yanagimoto M . Advances in understanding of angioimmunoblastic T-cell lymphoma[J]. Leukemia, 2020, 34 (10): 2592- 2606.
doi: 10.1038/s41375-020-0990-y
18 中国临床肿瘤学会肿瘤标志物专家委员会, 中国肿瘤驱动基因分析联盟. 二代测序技术在肿瘤精准医学诊断中的应用专家共识[J]. 中华医学杂志, 2018, 98 (26): 2057- 2065.
19 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会, 中华医学会病理学分会. 二代测序技术在血液肿瘤中的应用中国专家共识(2018年版)[J]. 中华血液学杂志, 2018, 39 (11): 881- 886.
20 Ondrejka SL , Grzywacz B , Bodo J , et al. Angioimmunoblastic T-cell lymphomas with the RHOA p.Gly17Val mutation have classic clinical and pathologic features[J]. Am J Surg Pathol, 2016, 40 (3): 335- 341.
doi: 10.1097/PAS.0000000000000555
21 张晨, 王小沛, 郑文, 等. 血管免疫母细胞性T细胞淋巴瘤42例临床分析[J]. 中华医学杂志, 2013, 93 (46): 3671- 3674.
22 Eladl AE , Shimada K , Suzuki Y , et al. EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma[J]. Cancer Med, 2020, 9 (2): 678- 688.
23 王芳, 张瑰红, 丁凯阳, 等. EBER、PTEN和VEGF在血管免疫母T细胞淋巴瘤中的表达及其临床病理学意义[J]. 中国实验血液学杂志, 2015, 23 (3): 663- 668.
24 Liang JH , Lu L , Zhu HY , et al. The prognostic role of circulating Epstein-Barr Virus DNA copy number in angioimmunoblastic T-cell lymphoma treated with dose-adjusted EPOCH[J]. Cancer Res Treat, 2019, 51 (1): 150- 157.
25 Kim TY , Min GJ , Jeon YW , et al. Impact of Epstein-Barr virus on peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma[J]. Front Oncol, 2021, 11, 797028.
[1] Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931.
[2] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[3] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[4] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[5] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[6] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[7] Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4+ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525.
[8] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[9] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[10] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
[11] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[12] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[13] Xiao-juan ZHU,Hong ZHANG,Shuang ZHANG,Dong LI,Xin LI,Ling XU,Ting LI. Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 243-253.
[14] Yu-mei LAI,Zhong-wu LI,Huan LI,Yan WU,Yun-fei SHI,Li-xin ZHOU,Yu-tong LOU,Chuan-liang CUI. Clinicopathological features and prognosis of anorectal melanoma: A report of 68 cases [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 262-269.
[15] Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd